Antigenics, Inc. (NASDAQ: AGEN)

Antigenics, Inc. (NASDAQ: AGEN) is focused on enhancing and extending the lives of patients by developing superior health care products for a broad array of cancers, infectious diseases and autoimmune disorders. Earlier this year, the company’s patient-specific cancer vaccine Oncophage ® (vitespen) was approved in Russia for the treatment of kidney cancer patients at intermediate risk for disease recurrence. Antigenics is now committed to exploring other major geographical territories for regulatory approval of Oncophage. For further information, visit the Company’s web site at www.antigenics.com.